As the clinical trial industry is facing lot of resistance in India, Industry experts are of the view that the Indian regulatory system should undergo massive reforms to contain unethical practices in clinical trials and should pave way to open up at least 10 per cent of global clinical trials in the country...According to N S Viswanathan, chief financial officer, Neuland Laboratories limited, the Indian drug regulatory system is very weak when compared to the US FDA, particularly in the clinical trials segment, the rules and protocols should be amended and strengthened so that it should not give any chance for the unscrupulous and rouge elements to take advantage of any loopholes in the regulations.